EUVIMEDEUVIMED entdecken
Open Access

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk

Julia Karady, Thomas Mayrhofer, Borek Foldyna, Michael T Lu, Nandini Meyersohn, Udo Hoffmann, Oluwafemi Balogon, Neha Pagidipati, Svati Shah, Pamela S Douglas, Maros Ferencik, Kathleen Corey iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Julia Karady und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Imaging Research Center, Harvard Medical School-Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Coronary Artery Disease, Fatty Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatic steatosis (HS) and 10‐year atherosclerotic cardiovascular disease (ASCVD) risk ≥ 7.5% are associated with increased risk for cardiovascular events.

Aim

To assess underlying coronary artery disease (CAD) and major adverse cardiovascular event (MACE) among those with and without HS at different ASCVD risk.

Methods

We evaluated stable chest pain patients receiving coronary computed tomography (CT) in the PROMISE trial. HS and CAD endpoints were defined on coronary CT. MACE was defined as unstable angina, non‐fatal myocardial infarction, and all‐cause death. Multivariable Cox regression, adjusting for CAD characteristics, assessed the association of HS with MACE for ASCVD < 7.5%.

Results

One thousand two hundred and four of 3702 (32.5%) patients were at ASCVD < 7.5% and 20.3% (244/1204) of them had HS. Individuals with HS were younger (54.3 ± 5.2 vs. 55.8 ± 5.2; p < 0.001), more often males (40.2% [98/244] vs. 27.1% [260/960]; p < 0.001), had more risk factors/person (2.06 ± 0.89 vs. 1.93 ± 0.91; p = 0.047). CAD characteristics were similar between HS vs. non‐HS patients at ASCVD < 7.5% and ASCVD ≥ 7.5% (all p > 0.05). Patients with HS had greater MACE rate compared to non‐HS patients (ASCVD < 7.5%: 3.75%[9/244] vs. 1.5% [14/960]; p = 0.027 and ASCVD ≥ 7.5%: 4.7% [33/696] vs. 3.1% [56/1802]; p = 0.043). In patients without HS, MACE rate was higher in the ASCVD ≥ 7.5% vs. < 7.5% (3.1% [56/1802] vs. 1.5% [14/960]; p = 0.011). In patients with HS, MACE rates were not significantly different between ASCVD ≥ 7.5% vs. < 7.5% (4.7% [33/696] vs. 3.7% [9/244]; p = 0.484). In ASCVD < 7.5%, HS predicted MACE (aHR:2.34, 95%CI:1.01–5.43; p = 0.048), independent of CAD characteristics.

Conclusions

Individuals with HS at ASCVD < 7.5% risk had similar CAD characteristics as patients without HS at < 7.5% ASCVD risk, yet experienced comparable MACE rates as those at ASCVD ≥ 7.5%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseFatty LiverHumansMaleFemaleMiddle AgedRisk FactorsTomography, X-Ray ComputedAtherosclerosisAgedMyocardial InfarctionCardiovascular Diseases

Stichwörter der Autor:innen

cardiovascular riskcoronary CT imagingcoronary artery diseasehepatic steatosismajor adverse cardiovascular events

Autor:innen und Institutionen

  • Cardiovascular Imaging Research Center, Harvard Medical School-Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany.
  • Cleerly Inc., Denver, Colorado, USA.
  • Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Kathleen Corey

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Karady, J., Mayrhofer, T., Foldyna, B., Lu, M. T., Meyersohn, N., Hoffmann, U., Balogon, O., Pagidipati, N., Shah, S., Douglas, P. S., Ferencik, M., & Corey, K. (2025). Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18415

Vancouver

Karady J, Mayrhofer T, Foldyna B, Lu MT, Meyersohn N, Hoffmann U, et al. Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18415

BibTeX
@article{Karady2025,
  author = {Karady, Julia and Mayrhofer, Thomas and Foldyna, Borek and Lu, Michael T and Meyersohn, Nandini and Hoffmann, Udo and Balogon, Oluwafemi and Pagidipati, Neha and Shah, Svati and Douglas, Pamela S and Ferencik, Maros and Corey, Kathleen},
  title = {Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18415}
}
Kostenlos starten →